Study summary

A B-cell antibody put six times as many people into complete remission as tacrolimus

MAJESTY trial (obinutuzumab) · 142 people, phase 3 · Published September 2026, New England Journal of Medicine

37%in complete remission at 2 years, vs 6% with tacrolimus

What was tested

Obinutuzumab, an intravenous antibody that removes B cells (the source of the PLA2R antibodies behind most cases), against tacrolimus, an oral immunosuppressant, for primary membranous nephropathy.

What they found

What it means

Likely to make obinutuzumab a leading first treatment for membranous nephropathy.

N Engl J Med, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.